Prerpints.org logo
Preprint
Article

The Impact of Culture Negativity on the Outcomes of Revision Total Knee Arthroplasty for Chronic PJI

Altmetrics

Downloads

89

Views

43

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

16 May 2024

Posted:

17 May 2024

You are already at the latest version

Alerts
Abstract
Culture-positive (CP) and culture-negative (CN) periprosthetic joint infections (PJI) remain a crucial area of research; however, current studies comparing these infections rely on unstandardized outcome reporting tools. Our study aimed to compare the outcomes of CP and CN PJI using the standardized Musculoskeletal Infection Society (MSIS) outcome reporting tool. We retrospectively reviewed 138 patients who were diagnosed with PJI and indicated for two-stage revision total knee arthroplasty (rTKA). The majority of patients in both CP and CN cohorts achieved infection control without the need for reoperation (54.1% and 62.5%, respectively). There was a significant difference in the overall distribution of MSIS outcomes (p=0.043), with a significantly greater rate of CN patients falling into Tier 1 (infection control without the use of suppressive antibiotics) (52.5% versus 29.6%, p=0.011). There was also a significant difference in the distribution of septic versus aseptic reoperations after 2nd stage (p=0.013), with more CP reoperations being septic and more CN reoperations being aseptic. The duration from 1st to 2nd stage was significantly shorter in the CN cohort (p=0.002). While overall infection control was similar between cohorts, these data suggest that the outcomes of two-stage rTKA are favorable in cases of CN PJI.
Keywords: 
Subject: Medicine and Pharmacology  -   Orthopedics and Sports Medicine

1. Introduction

Culture negative (CN) PJI is a rare but relatively prevalent phenomenon that poses a significant clinical challenge to physicians (Parvizi et al., 2014). The prevalence of CN PJI may be attributed to many factors, including the use of antibiotics prior to culture sampling or the delayed transport of such samples (Bejon et al., 2010; Tan et al., 2018). Additionally, the use of traditional culture mediums that are limited in their ability to grow atypical organisms, such as those that require a longer incubation period or that are encased in biofilms, are a possible cause of false-negative (CN) results (Kalbian et al., 2020). Regardless of the cause, CN PJI significantly complicates medical decision-making, from choice of antibiotics prescription to surgical treatment options (Yoon et al., 2017).
Research studies regarding outcomes following CN PJI have demonstrated differing results. Some scholars state that CN PJI yields worse outcomes as compared to those of culture positive (CP) PJI patients, arguing that the lack of identification of an infecting organism obscures treatment options and complicates both diagnosis and management of the infection (F. Li et al., 2023; Mortazavi et al., 2011). Others, however, have demonstrated that outcomes are more comparable or are even favorable for patients with CN PJI, attributing the negative culture to be indicative of a less severe infection (F. Li et al., 2023; H. Li et al., 2017; Tan et al., 2018). The controversy surrounding CP and CN PJI, and what the clinical implications are for each, indicates a need for further research in this area. The ambiguity surrounding CP versus CN PJI outcomes is compounded by the fact that current data comparing these infections rely on unstandardized outcome reporting tools (C. Xu et al., 2020). As such, the Musculoskeletal Infection Society developed an outcome reporting tool to both inform treatment decisions for physicians and provide standardization for researchers evaluating PJI (Fillingham et al., 2019).
Our study aimed to compare the outcomes of CP and CN PJI using this outcome reporting tool. We hypothesized that patients experiencing CN PJI would have unfavorable outcomes (thus, a higher MSIS outcome score) compared to those experiencing CP PJI. The results of this study will provide more standardized evidence of CN PJI outcomes, highlighting the gravity of these infections and informing future clinical decision-making in the context of these infections

2. Methods

2.1. Study Design

After obtaining Institutional Review Board (IRB) approval, we retrospectively reviewed a registry of 382 patients who were diagnosed with PJI following TKA from 2011 to 2022 at a single, tertiary academic medical center. Patients were included if they had a PJI diagnosis following TKA. We defined PJI according to the 2018 International Consensus Meeting (ICM) criteria (Abdelaziz et al., 2020; Levent et al., 2021; Parvizi et al., 2018; Shohat et al., 2019). As such, major criteria included a) two positive cultures of the same organism or b) the presence of a sinus tract with communication to the joint and/or prosthesis. Minor criteria were evaluated using a point system. Minor criteria included an elevated synovial white blood cell count (3 points), presence of intraoperative wound purulence (3 points), presence of positive histology (3 points), elevated synovial polymorphonuclear (PMN) percentage (2 points), presence of one positive culture (2 points), an elevated serum CRP (2 points), and an elevated serum ESR (1 point). Patients who had at least one major criterion were considered positive for PJI, and those who met minor criteria that amounted to > 6 points were also considered positive for PJI (S.-J. Kim & Cho, 2021; Parvizi et al., 2018).
Patients who met these criteria, who were indicated for two-stage revision TKA (rTKA), and who went on to complete at least stage one of the two-stage rTKA were included in the study. Patients who received debridement & irrigation and implant retention (DAIR) only as PJI treatment were excluded from the study. Patients whose demographic, surgical, and/or follow up data were incomplete were also excluded. Cohorts were then defined using the above criteria. Patients were placed in the CN PJI cohort if they met PJI criteria without having a positive culture on the day of their infection diagnosis. Patients who had a negative culture on the day of their infection diagnosis but a positive culture intraoperatively were placed in the CP cohort. All other patients were placed in the CP cohort.

2.2. Data Collection

Demographic variables including age, sex, race, smoking status, body mass index (BMI), and American Association of Anesthesiologists (ASA) class were collected for each patient. For patients in the CP cohort, the species of infecting organism was also recorded. Postoperative data including postoperative antibiotic use, follow-up duration, duration from 1st to 2nd stage, spacer retention status, incidence of unplanned reoperations (including septic and aseptic), and mortality were collected.
Using these outcomes data, patients were then categorized into tiers according to the 2018 MSIS outcomes reporting tool (Fillingham et al., 2019). Tier 1 was defined as infection control without the use of suppressive antibiotics and tier 2 as infection control with use of suppressive antibiotics. Suppressive antibiotic use was defined as the use of antibiotics for greater than one year postoperatively. Tier 3 was defined as the need for reoperation or as retention of spacer. Tier 3 was subdivided into 6 categories:
3A: Aseptic revision over one year after the start of PJI treatment
3B: Septic revision (i.e. DAIR) over one year after the start of PJI treatment (excluding amputation, resection arthroplasty, and arthrodesis)
3C: Aseptic revision less than one year from the start of PJI treatment
3D: Septic revision less than one year from the start of PJI treatment (excluding amputation, resection arthroplasty, and arthrodesis)
3E: Amputation, resection arthroplasty, or arthrodesis
3F: Spacer retention
Tier 4 was defined as all-cause mortality at any time following the initiation of PJI treatment. (Fillingham 2019)

2.3. Data Analysis

We perfumed all statistical analyses using SPSS v25 (IBM Corporation, Armonk, New York). All demographic and surgical outcomes data were assessed using chi square analyses and independent sample two-sided t-tests for categorical and continuous variables, respectively. We reported all categorical variables as frequencies with percentages, and we reported all continuous variables as means with standard deviations. Statistical significance was defined as the presence of a p-value ≤ 0.05.

3. Results

The final study population included 138 patients, with 98 patients in the CP cohort and 40 patients in the CN cohort. The average age of patients in the CP and CN cohorts was 64.01 and 61.25, respectively (p=0.176). The CP cohort was 48.0% male, and the CN cohort was 32.5% male (p=0.097). The average BMI was 31.75 and 33.70 in the CP and CN cohorts, respectively (p=0.145). The majority of patients in the CP and CN cohorts had an ASA score of 3 (58.2% for CP and 52.5% for CN; p=0.524). Complete results for demographic data can be found in Table 1.
Table 1. Comparison of demographic variables of between all patients in the CP and CN cohorts.
Table 1. Comparison of demographic variables of between all patients in the CP and CN cohorts.
Table 1. Demographic variables
CP (n=98) CN (n=40) P-value
Age at index revision, years [range] 64.01 [24-89] 61.25 [42-82] 0.176
Sex, n (%) 0.097
Male 47 (48.0) 13 (32.5)
Female 51 (52.0) 27 (67.5)
Race, n (%) 0.351
White 62 (63.3) 19 (47.5)
Black 16 (16.3) 9 (22.5)
Asian 2 (2.0) 2 (5.0)
Other 18 (18.4) 10 (25.0)
Smoking Status, n (%) 0.870
Never 52 (53.1) 23 (57.5)
Former 39 (39.8) 14 (35.0)
Current 7 (7.1) 3 (7.5)
BMI, mean [range] 31.75 [17-54.8] 33.70 [18.2-45.9] 0.145
ASA score, n (%) 0.524
1 4 (4.1) 0 (0)
2 30 (30.6) 15 (37.5)
3 57 (58.2) 21 (52.5)
4 6 (6.1) 4 (10.0)
5 1 (1.0) 0 (0)
CP, culture-positive; CN, culture-negative; BMI, body mass index; ASA, American Society of Anesthesiologists
Within the CP cohort, 113 infecting organisms were identified. The most prevalent infecting organism was Staphylococcus aureus, with 44 cases comprising 39.8% of all identified organisms. Of these cases, 14 were methicillin resistant. The next most prevalent infecting organism was Staphylococcus epidermidis, with 22 cases (19.5% of all identified organisms). Of all CP cases, 13 (13.3%) contained more than one infecting organism (polymicrobial infection). Complete results regarding infecting organisms can be found in Table 2.
Table 2. Infecting organisms identified in all patients within the CP cohort.
Table 2. Infecting organisms identified in all patients within the CP cohort.
Table 2. Infecting organism in the CP cohort
Organism N Percentage
Staphylococcus aureus 45 (methicillin resistant=14) 39.8
Staphylococcus epidermidis 22 19.5
Enterococcus faecalis 7 6.2
Pseudomonas aeruginosa 5 4.4
Staphylococcus lugdunensis 5 4.4
Streptococcus agalactiae 3 2.7
Klebsiella pneumoniae 3 2.7
Other 23 20.3
Total 113 100
CP, culture positive
There was a significant difference in the overall distribution of MSIS outcome scores between patients in the CP and CN cohorts (p=0.043). Significantly fewer patients in the CP cohort had an MSIS tier 1 outcome compared to patients in the CN cohort (29.6% versus 52.5%; p=0.011). There were no significant differences in the number of patients with MSIS tier 2, 3, or 4 outcomes between the two cohorts.
There were no significant differences in the incidence of unplanned reoperations between cohorts (p=0.737). 87.8% of patients in the CP cohort and 92.5% of those in the CN cohort completed the 2nd stage of their treatment plan (p=0.417). There was a 31.4% and 24.3% incidence of unplanned reoperation after 2nd stage in the CP and CN cohorts, respectively (p=0.429). There was a significant difference in the distribution of these revisions as septic versus aseptic, with aseptic revisions comprising 3.5% of CP and 13.5% of CN patients who completed the 2nd stage of their revision (p=0.013). The average follow-up duration was 1,249.06 days in the CP cohort and 1,497.08 days in the CN cohort (p=0.239). The average duration from 1st to 2nd stage was significantly longer in the CP cohort (209.08 days) compared to the CN cohort (139.65 days, p=0.002). Complete results for surgical outcomes data may be found in Table 3.
Table 3. Comparison of postoperative outcomes between the CP and CN cohorts according to the MSIS outcome reporting tool.
Table 3. Comparison of postoperative outcomes between the CP and CN cohorts according to the MSIS outcome reporting tool.
Table 3. Outcomes of two-stage revision
CP (n=98) CN (n=40) P-value
MSIS outcome, n (%) 0.043
1 29 (29.6) 21 (52.5) 0.011
2 24 (24.5) 4 (10.0) 0.055
3 43 (43.9) 15 (37.5) 0.491
3A 3 (3.1) 1 (2.5)
3B 3 (3.1) 4 (10.0)
3C 1 (1.0) 2 (5.0)
3D 21 (21.4) 3 (7.5)
3E 7 (7.1) 1 (2.5)
3F 8 (8.2) 4 (10.0)
4 2 (2.0) 0 (0) 0.363
Any unplanned reoperations between stages, n (%) 17 (17.3) 6 (15.0) 0.737
Completed 2nd stage, n (%) 86 (87.8) 37 (92.5) 0.417
Any unplanned reoperations after 2nd stage, n (%) 27/86 (31.4) 9/37 (24.3) 0.429
Aseptic 3/86 (3.5) 5/37 (13.5) 0.013
Septic 24/86 (27.9) 4/37 (10.8)
Follow-up duration, days [range] 1,249.06 [51-3,721] 1,497.08 [0-4,518] 0.239
Duration from 1st to 2nd stage, days [range] [64-854] 139.65 [54-444] 0.002
CP, culture-positive; CN, culture-negative; MSIS, Musculoskeletal Infection Society

4. Discussion

Among PJI cases in the United States, CN PJI is a rare occurrence in which the diagnosis of infection is made despite failure to grow microorganisms in culture (Henderson & Austin, 2017; Kang et al., 2018). Because a specific microorganism cannot be identified, CN PJI is difficult both to diagnose and to treat (Y.-H. Kim et al., 2015). In comparison to those of CP cases, the outcomes of CN PJI are not as well understood (Berbari et al., 2007). In an effort to compare the outcomes of CP and CN PJI using a standardized model, our study utilized the 2018 MSIS outcome reporting tool to compare the rate of infection control in patients undergoing two-stage rTKA for both CP and CN infections.
Our study demonstrated a significant difference in the distribution of MSIS outcomes between the two cohorts (p=0.043). The majority of CP patients fell into tier 3 (need for reoperation and/or spacer retention), while the majority of CN patients fell into tier 1 (infection control without the use of suppressive antibiotics). There was no significant difference in the number of patients with tier 3 outcomes (p=0.491); however, the percentage of patients with tier 1 outcomes was significantly lower in the CP cohort (29.6%) compared to the CN cohort (52.5%; p=0.011). While the majority of patients in both cohorts achieved infection control (tier 1 or tier 2), these initial results indicate that surgical outcomes following two-stage rTKA are more favorable for CN patients. A similar study by Xu et al. compared 53 CP and 24 CN PJI patients via Kaplan-Meier survival analysis and demonstrated comparable infection control between the two cohorts (p=0.897) (Z. Xu et al., 2022). An analogous study by Choi et al. compared the surgical outcomes of 135 CP PJI patients and 40 CN PJI patients, demonstrating an increased success rate of infection control for those in the CN PJI cohort (p=0.006) (Choi et al., 2013). However, neither of these studies were specific to TKA, and neither diagnosed PJI according to the 2018 ICM criteria. Most importantly, neither evaluated patient outcomes using the 2018 MSIS outcome reporting tool. To our knowledge, our study is among the first to address all three of these factors. Future studies should employ the MSIS outcome reporting tool in the setting of CP or CN PJI in an effort to continue standardizing outcomes measures for two-stage revisions in these patients.
While there was no significant difference in the number of unplanned reoperations after 2nd stage between cohorts (p=0.429), the distribution of those reoperations as septic versus aseptic was significantly different (p=0.013). While 27.9% of all CP patients who completed 2nd stage underwent septic reoperation, only 10.8% of CN patients underwent septic reoperation. Moreover, the majority of all reoperations in the CP cohort were septic, while the majority of reoperations in the CN cohort were aseptic. A similar study by Li et al. 2016 compared outcomes of CP and CN patients undergoing two-stage revision and demonstrated that 11.1% of CP patients experienced reinfection while only 7.34% of CN patients experienced reinfection. These results, however, were not statistically significant (p=0.94), and the comparison of reinfection to septic reoperation is not quite analogous. While several studies have shown statistically similar reoperation rates after 2nd stage between CP and CN PJI (C.-W. Kim et al., 2021; Lu et al., 2024), few to our knowledge have elucidated a difference specifically between septic versus aseptic reoperations. The implications of septic reoperation for TKA have been investigated across many studies, the majority of which demonstrating that septic reoperations are associated with reduced patient satisfaction scores, greater cost to patients and the healthcare system, and increased mortality rates (Choi & Bedair, 2014; Okafor et al., 2021; Wang et al., 2004). While these studies are not specific to reoperations following two-stage revision for PJI, they nonetheless indicate the gravity and significant burden of septic reoperations. As our study demonstrates that CP PJI result in a differentially higher ratio of septic reoperations, future studies should investigate the clinical and financial implications of such reoperations so as to inform clinicians in future decision-making.
Within this study, the time between 1st and 2nd stage revisions was significantly longer in the CP cohort than the CN cohort (209.08 days versus 165.9 days, respectively; p=0.002). There are several factors at play in determining the time to 2nd stage revision, including patient comorbidities, laboratory testing, and surgeon preference (F. Li et al., 2023; Puetzler et al., 2023). As previously discussed, while the reoperation rates between cohorts were similar, the distribution of septic versus aseptic revisions was significantly different, with the CP PJI cohort undergoing nearly three times as many septic reoperations as the CN cohort. Thus, our study concurrently demonstrated that CP PJI yield more instances of septic reoperation and a longer time to reimplantation. It would be interesting for future studies to explore the relationship between time to reimplantation and septic reoperations in the context of CP and CN PJI. Specifically, studies investigating whether CP PJI and/or time to reimplantation are causative of septic revisions may provide clarity to this area of study.
There are several limitations to this study that should be noted. Firstly, while we attempted to standardize CN PJI diagnosis using the 2018 ICM criteria, there are still several clinical factors that may obscure the parameters of CN PJI diagnosis. In general, infections that are identified as culture-negative may appear as such because of faulty laboratory techniques (such as an inadequate culturing period) or prior antibiotic use before testing (Kalbian et al., 2020; Malekzadeh et al., 2010). While the use of antibiotics prophylactically prior to culture sampling has been debated (Della Valle et al., 2010; Zmistowski et al., 2014), such practice does pose a risk for culture-negative results. Future studies should investigate whether CN PJI patients used prophylactic antibiotics and consider whether this practice has any effect on surgical outcomes. A second limitation is that our study is retrospective in nature; therefore, our data was prone to errors of medical recording and prone to selection bias. A final limitation of this study is the small sample size of CN cases relative to CP cases. The incidence of PJI following TKA is rare to begin with, and the incidence of CN PJI is rarer still (Boddapati et al., 2018). However, considering the gravity of both CP and CN PJI, more research on the topic of these infections is merited and would greatly benefit surgeons in the long-term.

5. Conclusions

Our study compared the outcomes of CP and CN PJI utilizing the standardized MSIS outcome reporting tool. While the majority of patients in both cohorts achieved infection control without the need for reoperation, the distribution of MSIS outcomes was variable, with a significantly greater number of CN patients falling into tier 1 as compared to the CP cohort. Although treatment of CN PJI may be more challenging for physicians, these initial results demonstrate that CN PJI may in fact have a better prognosis. Future projects should utilize these results of this study to explore treatment options for CN PJI.

References

  1. Abdelaziz: H., Rademacher, K., Suero, E. M., Gehrke, T., Lausmann, C., Salber, J., & Citak, M. (2020). The 2018 International Consensus Meeting Minor Criteria for Chronic Hip and Knee Periprosthetic Joint Infection: Validation From a Single Center. The Journal of Arthroplasty, 35(8), 2200–2203. [CrossRef]
  2. Bejon, P., Berendt, A., Atkins, B. L., Green, N., Parry, H., Masters, S., Mclardy-Smith, P., Gundle, R., & Byren, I. (2010). Two-stage revision for prosthetic joint infection: Predictors of outcome and the role of reimplantation microbiology. Journal of Antimicrobial Chemotherapy, 65(3), 569–575. [CrossRef]
  3. Berbari, E. F., Marculescu, C., Sia, I., Lahr, B. D., Hanssen, A. D., Steckelberg, J. M., Gullerud, R., & Osmon, D. R. (2007). Culture-Negative Prosthetic Joint Infection. Clinical Infectious Diseases, 45(9), 1113–1119. [CrossRef]
  4. Boddapati, V., Fu, M. C., Mayman, D. J., Su, E. P., Sculco, P. K., & McLawhorn, A. S. (2018). Revision Total Knee Arthroplasty for Periprosthetic Joint Infection Is Associated With Increased Postoperative Morbidity and Mortality Relative to Noninfectious Revisions. The Journal of Arthroplasty, 33(2), 521–526. [CrossRef]
  5. Choi, H.-R., & Bedair, H. (2014). Mortality Following Revision Total Knee Arthroplasty: A Matched Cohort Study of Septic versus Aseptic Revisions. The Journal of Arthroplasty, 29(6), 1216–1218. [CrossRef]
  6. Choi, H.-R., Kwon, Y.-M., Freiberg, A. A., Nelson, S. B., & Malchau, H. (2013). Periprosthetic Joint Infection with Negative Culture Results: Clinical Characteristics and Treatment Outcome. The Journal of Arthroplasty, 28(6), 899–903. [CrossRef]
  7. Della Valle, C., Parvizi, J., Bauer, T. W., DiCesare, P. E., Evans, R. P., Segreti, J., Spangehl, M., Watters, W. C. I., Keith, M., Turkelson, C. M., Wies, J. L., Sluka, P., & Hitchcock, K. (2010). Diagnosis of Periprosthetic Joint Infections of the Hip and Knee. JAAOS - Journal of the American Academy of Orthopaedic Surgeons, 18(12), 760010). Diagnosis of Periprosthetic Joint Infections of the Hip and Knee.
  8. . Fillingham, Y. A., Della Valle, C. J., Suleiman, L. I., Springer, B. D., Gehrke, T., Bini, S. A., Segreti, J., Chen, A. F., Goswami, K., Tan, T. L., Shohat, N., Diaz-Ledezma, C., Schwartz, A. J., & Parvizi, J. (2019). Definition of Successful Infection Management and Guidelines for Reporting of Outcomes After Surgical Treatment of Periprosthetic Joint Infection: From the Workgroup of the Musculoskeletal Infection Society (MSIS). JBJS, 101(14), e69. JBJS. [CrossRef]
  9. Henderson, R. A., & Austin, M. S. (2017). Management of Periprosthetic Joint Infection: The More We Learn, the Less We Know. The Journal of Arthroplasty, 32(7), 2056–2059. [CrossRef]
  10. Kalbian, I., Park, J. W., Goswami, K., Lee, Y.-K., Parvizi, J., & Koo, K.-H. (2020). Culture-negative periprosthetic joint infection: Prevalence, aetiology, evaluation, recommendations, and treatment. International Orthopaedics, 44(7), 1255–1261. [CrossRef]
  11. Kang, J.-S., Shin, E.-H., Roh, T.-H., Na, Y., Moon, K. H., & Park, J.-H. (2018). Long-term clinical outcome of two-stage revision surgery for infected hip arthroplasty using cement spacer: Culture negative versus culture positive. Journal of Orthopaedic Surgery, 26(1), 2309499017754095. [CrossRef]
  12. Kim, C.-W., Lee, C.-R., Park, D.-H., Kim, D.-Y., & Kim, J.-W. (2021). Clinical outcomes of two-stage revision for chronic periprosthetic joint infection of the knee: Culture-negative versus culture-positive. Knee Surgery & Related Research, 33(1), 28. [CrossRef]
  13. Kim, S.-J., & Cho, Y. J. (2021). Current Guideline for Diagnosis of Periprosthetic Joint Infection: A Review Article. Hip & Pelvis, 33(1), 11–17. [CrossRef]
  14. Kim, Y.-H., Park, J.-W., Kim, J.-S., & Kim, D.-J. (2015). The outcome of infected total knee arthroplasty: Culture-positive versus culture-negative. Archives of Orthopaedic and Trauma Surgery, 135(10), 1459–1467. [CrossRef]
  15. Levent, A., Neufeld, M. E., Piakong, P., Lausmann, C., Gehrke, T., & Citak, M. (2021). Which International Consensus Meeting Preoperative Minor Criteria is the Most Accurate Marker for the Diagnosis of Periprosthetic Joint Infection in Hip and Knee Arthroplasty? The Journal of Arthroplasty, 36(11), 3728–3733. [CrossRef]
  16. Li, F., Qiao, Y., Zhang, H., Cao, G., & Zhou, S. (2023). Comparable clinical outcomes of culture-negative and culture-positive periprosthetic joint infections: A systematic review and meta-analysis. Journal of Orthopaedic Surgery and Research, 18(1), 210. [CrossRef]
  17. Li, H., Ni, M., Li, X., Zhang, Q., Li, X., & Chen, J. (2017). Two-stage revisions for culture-negative infected total knee arthroplasties: A five-year outcome in comparison with one-stage and two-stage revisions for culture-positive cases. Journal of Orthopaedic Science, 22(2), 306–312. [CrossRef]
  18. Lu, H., Wang, W., Xu, H., Zhou, K., & Zhou, Z. (2024). Efficacy and safety of two-stage revision for patients with culture-negative versus culture-positive periprosthetic joint infection: A single-center retrospective study. BMC Musculoskeletal Disorders, 25(1), 160. [CrossRef]
  19. Malekzadeh, D., Osmon, D. R., Lahr, B. D., Hanssen, A. D., & Berbari, E. F. (2010). Prior Use of Antimicrobial Therapy is a Risk Factor for Culture-negative Prosthetic Joint Infection. Clinical Orthopaedics and Related Research®, 468(8), 2039–2045. [CrossRef]
  20. Mortazavi, S. M. J., Vegari, D., Ho, A., Zmistowski, B., & Parvizi, J. (2011). Two-stage Exchange Arthroplasty for Infected Total Knee Arthroplasty: Predictors of Failure. Clinical Orthopaedics and Related Research®, 469(11), 3049–3054. [CrossRef]
  21. Okafor, C., Hodgkinson, B., Nghiem, S., Vertullo, C., & Byrnes, J. (2021). Cost of septic and aseptic revision total knee arthroplasty: A systematic review. BMC Musculoskeletal Disorders, 22(1), 706. [CrossRef]
  22. Parvizi, J., Erkocak, O. F., & Della Valle, C. J. (2014). Culture-Negative Periprosthetic Joint Infection. JBJS, 96(5), 430. [CrossRef]
  23. Parvizi, J., Tan, T. L., Goswami, K., Higuera, C., Della Valle, C., Chen, A. F., & Shohat, N. (2018). The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria. The Journal of Arthroplasty, 33(5), 1309-1314.e2. [CrossRef]
  24. Puetzler, J., Schulze, M., Gosheger, G., Schwarze, J., Moellenbeck, B., & Theil, C. (2023). Is long time to reimplantation a risk factor for reinfection in two-stage revision for periprosthetic infection? A systematic review of the literature. Frontiers in Surgery, 10. https://doi.org/10.3389/fsurg.2023.1113006. [CrossRef]
  25. Shohat, N., Bauer, T., Buttaro, M., Budhiparama, N., Cashman, J., Valle, C. J. D., Drago, L., Gehrke, T., Gomes, L. S. M., Goswami, K., Hailer, N. P., Han, S. B., Higuera, C. A., Inaba, Y., Jenny, J.-Y., Kjaersgaard-Andersen, P., Lee, M., Llinás, A., Malizos, K., … Zimmerli, W. (2019). Hip and Knee Section, What is the Definition of a Periprosthetic Joint Infection (PJI) of the Knee and the Hip? Can the Same Criteria be Used for Both Joints?: Proceedings of International Consensus on Orthopedic Infections. The Journal of Arthroplasty, 34(2), S325–S327. [CrossRef]
  26. Tan, T. L., Kheir, M. M., Shohat, N., Tan, D. D., Kheir, M., Chen, C., & Parvizi, J. (2018). Culture-Negative Periprosthetic Joint Infection: An Update on What to Expect. JBJS Open Access, 3(3), e0060. [CrossRef]
  27. Wang, C.-J., Hsieh, M.-C., Huang, T.-W., Wang, J.-W., Chen, H.-S., & Liu, C.-Y. (2004). Clinical outcome and patient satisfaction in aseptic and septic revision total knee arthroplasty. The Knee, 11(1), 45–49. [CrossRef] [PubMed]
  28. Xu, C., Tan, T. L., Li, W. T., Goswami, K., & Parvizi, J. (2020). Reporting Outcomes of Treatment for Periprosthetic Joint Infection of the Knee and Hip Together With a Minimum 1-Year Follow-Up is Reliable. The Journal of Arthroplasty, 35(7), 1906-1911.e5. [CrossRef]
  29. Xu, Z. Xu, Z., Huang, C., Lin, Y., Chen, Y., Fang, X., Huang, Z., Zhang, C., Zhang, Z., & Zhang, W. (2022). Clinical Outcomes of Culture-Negative and Culture-Positive Periprosthetic Joint Infection: Similar Success Rate, Different Incidence of Complications. Orthopaedic Surgery, 14(7), 1420–1427. [CrossRef]
  30. Yoon, H.-K., Cho, S.-H., Lee, D.-Y., Kang, B.-H., Lee, S.-H., Moon, D.-G., Kim, D.-H., Nam, D.-C., & Hwang, S.-C. (2017). A Review of the Literature on Culture-Negative Periprosthetic Joint Infection: Epidemiology, Diagnosis and Treatment. Knee Surgery & Related Research, 29(3), 155–164. [CrossRef]
  31. Zmistowski, B., Valle, C. D., Bauer, T. W., Malizos, K. N., Alavi, A., Bedair, H., Booth, R. E., Choong, P., Deirmengian, C., Ehrlich, G. D., Gambir, A., Huang, R., Kissin, Y., Kobayashi, H., Kobayashi, N., Krenn, V., Lorenzo, D., Marston, S. B., Meermans, G., … Witzo, E. (2014). Diagnosis of Periprosthetic Joint Infection. The Journal of Arthroplasty, 29(2), 77–83. [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated